Ora Inc. 03.31.16
Ora Inc., a developer of ophthalmic pharmaceuticals and devices, has appointed Simon Chandler, Ph.D., as senior director, tasked with leading regulatory and clinical operations in Europe.
Chandler will be based in the United Kingdom. Ora currently supports ophthalmology drug and device companies in Europe at all stages of product development with a broad range of services including: preclinical research, regulatory strategy, clinical trial execution, data management, statistics, medical writing, manufacturing expertise, quality assurance, business development and financing.
“Our clients demand global clinical trial execution with in-depth regional knowledge and deep category expertise in ophthalmology. Dr. Chandler is a key addition to Ora’s team and brings extensive experience in global clinical and regulatory operations, including overseeing approvals by the FDA, EMA and PMDA. His current experience in gene therapy is highly relevant given the potential of this new therapeutic modality to address unmet patient needs,” said Stuart B. Abelson, Ora’s president and CEO.
Chandler has more than 15 years of ophthalmic industry experience across Europe and the United States, focusing on retina and anterior segment indications. He has led successful drug development teams in anti-infective, anti-allergic, glaucoma and refractive surgery. Chandler has a bachelor's degree in molecular biology from the University of Portsmouth and a Ph.D. in epigenetic gene regulation from the University of Southampton, both in the United Kingdom.
“I have personally experienced the quality, timely execution, and strategic planning Ora delivers to ensure successful programs for their industry partners. I am proud to be joining a company with expertise in ophthalmology and a commitment to scientific rigor and innovation,” said Chandler.
Ora is a full-service ophthalmic contract research organization and product development firm with offices in the United States, the United Kingdom and Japan. Over the past 30 years, the company has helped clients earn 41 product approvals.
Chandler will be based in the United Kingdom. Ora currently supports ophthalmology drug and device companies in Europe at all stages of product development with a broad range of services including: preclinical research, regulatory strategy, clinical trial execution, data management, statistics, medical writing, manufacturing expertise, quality assurance, business development and financing.
“Our clients demand global clinical trial execution with in-depth regional knowledge and deep category expertise in ophthalmology. Dr. Chandler is a key addition to Ora’s team and brings extensive experience in global clinical and regulatory operations, including overseeing approvals by the FDA, EMA and PMDA. His current experience in gene therapy is highly relevant given the potential of this new therapeutic modality to address unmet patient needs,” said Stuart B. Abelson, Ora’s president and CEO.
Chandler has more than 15 years of ophthalmic industry experience across Europe and the United States, focusing on retina and anterior segment indications. He has led successful drug development teams in anti-infective, anti-allergic, glaucoma and refractive surgery. Chandler has a bachelor's degree in molecular biology from the University of Portsmouth and a Ph.D. in epigenetic gene regulation from the University of Southampton, both in the United Kingdom.
“I have personally experienced the quality, timely execution, and strategic planning Ora delivers to ensure successful programs for their industry partners. I am proud to be joining a company with expertise in ophthalmology and a commitment to scientific rigor and innovation,” said Chandler.
Ora is a full-service ophthalmic contract research organization and product development firm with offices in the United States, the United Kingdom and Japan. Over the past 30 years, the company has helped clients earn 41 product approvals.